The Health departmental officials said that “a new plan will be shared" for when the funding ends in March 2026.

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

The populations with the greatest disparities are adolescents, Black and Hispanic patients, and those with public or no ...

One in ten clinics in South Africa — across 22 health districts in six provinces — could start to hand out a twice-a-year anti-HIV jab as early as February if the country’s medicines regulator ...

For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

Event Information: Event NanoViricides Presentation at the Spartan Capital Investor Conference ... as well as in the course of most of the other viral epidemics including Influenza and HIV/AIDS.

Q3 2025 Earnings Call October 30, 2025 4:30 PM EDTCompany ParticipantsJacquie Ross - Senior Vice President of Treasury ...

Globally, synovial sarcoma remains a rare but aggressive malignancy with a 5-year survival rate of 70% to 80% and a 10-year ...

Catch up on the biggest stories of Tuesday, 28 October 2025 that you may have missed, in our simple daily news update.

INDICATION AUCATZYL ® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...

GSK plc ( GSK) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Ladies and gentlemen, a very warm welcome to the GSK Q3 2025 Results Call. I'm delighted to be joined today by Emma Walmsley, Luke ...